重症监护儿童维生素D缺乏快速纠正(VITdALIZE-KIDS):一项III期多中心随机对照试验的研究方案
VITdALIZE-KIDS是一项III期多中心双盲随机对照试验,计划纳入加拿大儿童重症监护病房的766名危重患儿,按1:1随机接受单剂肠内胆钙化醇(10,000 IU/kg,最大400,000 IU)或安慰剂。主要目的是评估快速纠正维生素D状态能否改善入组后28天的健康相关生活质量,次要目的为评估对多器官功能障碍的影响。
要点
- 针对危重患儿维生素D缺乏(全球估计发生率50%)的快速纠正策略。
- 单剂肠内胆钙化醇10,000 IU/kg(最大400,000 IU)与安慰剂对照。
- 主要结局为入组后28天健康相关生活质量,次要结局为多器官功能障碍。
核心结论
- 该试验旨在评估快速纠正维生素D状态是否可作为改善儿童危重病后结局的简单、廉价且安全的手段。
研究设计与样本
- VITdALIZE-KIDS是一项实用性、III期、多中心、双盲随机对照试验,计划从加拿大儿童重症监护病房随机纳入766名危重患儿,按1:1方案随机分组。
主要发现
- 全球危重儿童维生素D缺乏发生率估计为50%。
- 研究组II期多中心剂量评估预试验已确定基于体重的肠内胆钙化醇负荷剂量可快速恢复危重患儿维生素D水平的疗效和安全性。
- 入组标准包括校正胎龄>37周的新生儿至<18岁的危重患儿,且血总25-羟基维生素D<50 nmol/L。
- 受试者在入组时接受单剂肠内胆钙化醇10,000 IU/kg(最大400,000 IU)或安慰剂。
- 主要目的是确定快速纠正维生素D状态能否改善入组后28天的健康相关生活质量,次要目的是评估其对多器官功能障碍的影响。
关键数值与推荐
- 干预措施:单剂肠内胆钙化醇10,000 IU/kg,最大400,000 IU。
- 纳入标准:校正胎龄>37周的新生儿至<18岁,血总25-羟基维生素D<50 nmol/L。
- 主要结局:入组后28天健康相关生活质量。
- 次要结局:多器官功能障碍。
- 其他结局包括出院和90天时的功能状态、健康相关生活质量和死亡率、儿童重症监护病房和住院时间、与维生素D毒性相关的不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rate of vitamin D deficiency (VDD) in critically ill children worldwide has been estimated at 50%. These children are at risk of multiple organ dysfunction, chronic morbidity, and decreased health related quality of life (HRQL). Pediatric and adult ICU clinical trials suggest that VDD is associated with worse clinical outcomes, although data from supplementation trials are limited and inconclusive. Our group's phase II multicenter dose evaluation pilot study established the efficacy and safety of an enteral weight-based cholecalciferol loading dose to rapidly restore vitamin D levels in critically ill children. METHODS: Our aim is to evaluate the impact of this dosing regimen on clinical outcomes. VITdALIZE-KIDS is a pragmatic, phase III, multicenter, double-blind RCT aiming to randomize 766 critically ill children from Canadian PICUs. Participants are randomized using a 1:1 scheme to receive a single dose at enrollment of enteral cholecalciferol (10,000 IU/kg, max 400,000 IU) or placebo. Eligibility criteria include critically ill children aged newborn (> 37 weeks corrected gestational age) to < 18 years who have blood total 25-hydroxyvitamin D < 50 nmol/L. The primary objective is to determine if rapid normalization of vitamin D status improves HRQL at 28 days following enrollment. The secondary objective is to evaluate the impact of rapid normalization of vitamin D status on multiple organ dysfunction. The study includes additional tertiary outcomes including functional status, HRQL and mortality at hospital discharge and 90 days, PICU and hospital length of stay, and adverse events related to vitamin D toxicity. Additionally, we are performing comprehensive vitamin D speciation and non-targeted metabolite profiling as part of a sub-study for the first 100 participants from whom an enrollment and at least one post-intervention blood and urine sample were obtained. DISCUSSION: The VITdALIZE-KIDS trial is the first phase III, multicenter trial to evaluate whether rapid normalization of vitamin D status could represent a simple, inexpensive, and safe means of improving outcomes following pediatric critical illness. Recruitment was initiated in June 2019 and is expected to continue to March 2026. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03742505. Study first submitted on November 12, 2018 https://clinicaltrials.gov/study/NCT03742505.
引用
- O'Hearn K, Menon K, Albrecht L, et al. Rapid normalization of vitamin D deficiency in PICU (VITdALIZE-KIDS): study protocol for a phase III, multicenter randomized controlled trial. Trials. 2024. PMID: 39300483. doi:10.1186/s13063-024-08461-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。